Biopharmaceutical company Sirnaomics Ltd., together with its subsidiaries (stock code: 2257), announced on Thursday that it has dosed the first subject in a phase one clinical trial of STP122G for anticoagulation treatment.

The product is part of the Group's GalAhead Factor XI RNAi therapeutic programme that has applications across a wide range of disease indications such as the potential prevention and treatment of stroke after atrial fibrillation, cancer subjects after immunotherapy and improving total knee replacement recovery.

The trial, a phase I, single-centre, randomised, double-blind, sequential cohort study, is to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of a single ascending dose of STP122G when administered subcutaneously to healthy subjects.

The safety and tolerability are to be compared among five different doses of STP122G (25mg, 50mg, 100mg, 200mg, 400mg) to select one for future studies. The study is planning to hire a total of 40 participants.